Nutra Pharma Has Announced That Its Over-the-Counter (OTC) Pain Reliever, Cobroxin, Has Generated Sales Totaling $583,955 for the Fourth Quarter Ending December 31, 2009
PLANTATION, Fla., Feb 02, 2010 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.
"We were extremely pleased with our fourth quarter Cobroxin sales, especially given its initial limited retail availability," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "With the positive feedback we have received from Cobroxin consumers and retailers, we remain optimistic about the future growth of Cobroxin as we move into 2010," he added.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which began selling in mid-October 2009, is currently available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Cobroxin's additional benefits include:
-- All Natural
-- Non-Addictive
-- Non-Narcotic
-- Non-Opiate
-- Long Lasting
Cobroxin is currently sold online and through brick-and-mortar retailers and is distributed by XenaCare Holdings (OTCBB: XCHO), a consumer products company, which is licensed to market and distribute Cobroxin throughout the United States.
About Nutra Pharma Corp.
Nutra Pharma Corporation (the "Company") operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with.
http://www.NutraPharma.com
http://www.Cobroxin.com
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
Kevin McKnight1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212Boca Raton, FL
33432
www.undiscoveredequities.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment